diabetes glp-1 vs sglt2 Cardiorenal Protection: Potential of Inhibitors and Receptor Agonists in the Treatment of Type 2 | Diabetes Therapy GLP-1 Receptor Agonist Therapy With
Description
WMD = 2.30 kg, 95% CI 0.53 to 4.07, P = 0.01, 2 = 0.0%
Staying hydrated prevents electrolyte depletion, and eating smaller, more frequent meals reduces the digestive load on a stomach that already empties slowly
Glycine has been studied extensively for its effects on sleep quality
These symptoms warrant a conversation with your medical provider
doi: 10.1172/JCI15784 128 ToyotaHDugovicCKoehlMLaposkyADWeberCNgoKet al
#GLP1 #Semaglutida #Tirzepatida #Obesidad #Diabetes #MedicinaInterna #Endocrinologa #DrSoquendo
